Thrombotic microangiopathy (TMA) is a serious complication that may occur in patients with systemic lupus erythematosus (SLE), adversely affecting the prognosis and increasing mortality. The pathogenesis of TMA in these patients may be multifactorial and overlap between different entities may exist.

Introduction: Thrombotic microangiopathy (TMA) is a life-threatening, albeit infrequent, complication of systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS). Recommendations for the treatment of SLE- and APS-related secondary TMA are currently based solely on case reports and expert opinion.

Aug 22, 2022 · Thrombotic microangiopathy (TMA) is a syndrome associated with hemolytic anemia, thrombocytopenia, and various organ disorders . Collagen diseases have been reported to be the most common underlying cause of secondary TMA, among which systemic lupus erythematosus (SLE) is the most common .

Thrombotic microangiopathy (TMA) is a serious complication that can occur in patients with systemic lupus erythematosus (SLE), and TMA adversely affects prognosis and increases mortality. The treatment of TMA often requires immunosuppressive agents, ...

Dec 7, 2017 · Complement inhibition, with eculizumab, is an effective treatment of patients with progressive lupus nephritis associated TMA and represents a new paradigm in treatment for this devastating disorder.

Thrombotic microangiopathy (TMA) is a severe disorder with poor outcomes. The cause is unknown for many patients, although TMA is associated with connective tissue disorders, including systemic lupus ery-thematosus (SLE). While uncommon, TMA is one of the most serious complications of SLE and in many cases may be resistant to therapy.

This case report reveals that eculizumab is effective in controlling TMA in a patient with lupus. We believe that a randomized, controlled, multicenter trial that evaluates eculizumab and plasmapheresis treatment for acute TMA in patients with lupus is warranted.

3 days ago · Thrombotic microangiopathy (TMA) is an independent prognostic factor of systemic lupus erythematosus (SLE) and results in higher mortality and higher risk of developing end-stage renal disease (ESRD). 1 Among SLE patients, the prevalence of TMA is approximately 1% 2, but a previous study based on lupus nephritis (LN) kidney biopsy suggested that TMA manifested in 24.3% LN patients. 3 TMA can ...

Aug 21, 2018 · Lupus erythematosus is a multisystem immune complex disorder associated with activation of complement, as well as renal failure termed lupus nephritis (LN). A subset of these patients also develop TMA, with progressive life-threatening thrombocytopenia, MAHA, and progressive renal failure similar to aHUS.

Nov 1, 2018 · Thrombotic microangiopathy (TMA) is an uncommon and usually severe manifestation of systemic lupus erythematosus (SLE), characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, organ …